Pituistat label

Pituistat

Pituistat Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

Do not use if tamper evident seal is broken or missing. Store in a cool, dry place.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

For temporary relief of mental sluggishness, confusion, weakness, lethargy, thirst and frequent urination.**

**These statements are based upon traditional homeopathic practice. They have not been reviewed by the Food and Drug Administration.

History

There is currently no drug history available for this drug.

Other Information

There are no additional details available for this product.

Pituistat Manufacturers

  • Energique, Inc.
    Pituistat | Sebela Pharmaceuticals Inc.
    No Recall

    Pituistat | Sebela Pharmaceuticals Inc.

    Pituistat | Sebela Pharmaceuticals Inc.
    2.1     Paget’s Disease of Bone

    The recommended dose of Miacalcin injection for treatment of symptomatic Paget's disease of bone is 100 International Units (0.5 mL) per day administered subcutaneously or intramuscularly.

    2.2     Hypercalcemia

    The recommended starting dose of Miacalcin injection for early treatment of hypercalcemia is 4 International Units/kg body weight every 12 hours by subcutaneous or intramuscular injection. If the response to this dose is not satisfactory after one or two days, the dose may be increased to 8 International Units/kg every 12 hours. If the response remains unsatisfactory after two more days, the dose may be further increased to a maximum of 8 International Units/kg every 6 hours.

    2.3     Postmenopausal Osteoporosis

    The recommended dose of Miacalcin injection for treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause is 100 International Units (0.5 mL) per day administered subcutaneously or intramuscularly. The minimum effective dose of Miacalcin injection for the prevention of vertebral bone mineral density loss has not been established.

    2.4     Preparation and Administration

    Visually inspect Miacalcin vials. Miacalcin injection is a clear, colorless, solution. If the solution is not clear and colorless, or contains any particles, or if the vial is damaged, do not administer the solution. If the volume of Miacalcin injection to be injected exceeds 2 mL, intramuscular injection is preferable and the total dose should be distributed across multiple sites of injection. Instruct patients to use sterile injection technique when administering Miacalcin injection, and to dispose of needles properly.

    2.5     Recommendations for Calcium and Vitamin D Supplementation

    Patients who use Miacalcin injection for treatment of postmenopausal osteoporosis should receive adequate calcium (at least 1000 mg elemental calcium per day) and vitamin D (at least 400 International Units per day).